Madrigal Pharmaceuticals Inc.
Rating
Updated: Sep 18, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, ...
Latest News
12 days ago · seekingalpha.com
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptMadrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
12 days ago · fool.com
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?Madrigal's only commercial drug, Rezdiffra, continues to grow sales. Institutional investors hold more than 95% of the stock's float.
28 days ago · fool.com
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take OffMASH cirrhosis could significantly expand Rezdiffra's addressable market. Madrigal's developing pipeline could reduce its dependence on Rezdiffra.
1 month ago · defenseworld.net
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline ExpandsMadrigal Pharmaceuticals (NASDAQ: MDGL) said Rezdiffra continued to post strong commercial growth in the second quarter of 2026, while the company expanded its development pipeline around the MASH therapy and prepared for several potential clinical catalysts. Speaking at a Canaccord Genuity event, Chief Financial Officer Mardi Dier said the company reported $364 million in second-quarter revenue,
1 month ago · globenewswire.com
Madrigal Appoints John C. Reed, M.D.CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed John C.
1 month ago · seekingalpha.com
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference TranscriptMadrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
2 months ago · globenewswire.com
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth ConferenceCONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, Aug. 11, 2026 at 12:00 P.M. EDT.
2 months ago · zacks.com
MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y GrowthMadrigal beats Q2 estimates as Rezdiffra sales lift revenues 71% year over year, but shares fall as investors weigh slower commercial growth.
2 months ago · marketbeat.com
Madrigal Pharmaceuticals Q2 Earnings Call HighlightsMadrigal Pharmaceuticals NASDAQ: MDGL reported second-quarter 2026 net sales of $364.3 million for Rezdiffra, up 71% from a year earlier, as the company continued to expand the number of patients receiving its treatment for metabolic dysfunction-associated steatohepatitis, or MASH.
2 months ago · seekingalpha.com
Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2026 Earnings Call TranscriptMadrigal Pharmaceuticals, Inc. (MDGL) Q2 2026 Earnings Call Transcript
Analyst Summary
Add to Watchlist
Select watchlists to add or remove MDGL